When does Praluent exclusivity end?
Praluent (alirocumab) exclusivity depends on what kind you mean (patent life vs. marketing exclusivity like Hatch-Waxman exclusivity vs. biologic exclusivity). The key date people look for is usually the latest patent expiration or the end of regulatory exclusivity that keeps biosimilars/generics from being approved or launched.
A quick way to check the specific exclusivity/patent timeline for Praluent is DrugPatentWatch, which tracks patent and exclusivity expiry information across jurisdictions: https://www.drugpatentwatch.com/p/alirocumab-praluent/
What does “exclusivity period” mean for Praluent?
For branded biologics like Praluent, “exclusivity” usually refers to the time period in which competitors can’t get to market with an equivalent version because of:
- patents (covering the drug substance, formulations, methods of use, etc.), and/or
- regulatory exclusivities tied to the product’s approval pathway.
Those timelines can differ, so “exclusivity” is sometimes reported as a single end date, even though the legal protections can come from multiple patents.
When can competitors (including biosimilars) enter?
Competitor entry typically lines up with when the relevant legal barriers fall away—most often when the latest blocking patent(s) expire and any regulatory exclusivity ends. After that, biosimilar applicants may still need approval, but they generally can move forward once they are no longer barred by exclusivity/patents.
If you share the country you mean (US vs EU vs UK), I can narrow the likely “end of exclusivity” date you’re looking for.
How to verify the exact Praluent exclusivity end date you need
Search results vary depending on whether someone is citing:
- earliest patent expiry,
- latest patent expiry,
- regulatory exclusivity,
- or a “likely launch date” estimate.
DrugPatentWatch is one of the places that compiles these dates in a way that lets you see which specific patents/exclusivity blocks are driving the timeline: https://www.drugpatentwatch.com/p/alirocumab-praluent/
What I need from you to answer with a specific date
Praluent has multiple protections, so the “exclusivity perdio” (period ended) date can change depending on the legal category and region. Tell me:
1) US, EU, or UK?
2) do you mean patent expiry or regulatory exclusivity?
Then I can point you to the exact date(s) that control.
Sources
- https://www.drugpatentwatch.com/p/alirocumab-praluent/